Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739240 | 1.00 | PRCP (0.46) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| SCHEMBL737577 | 1.00 | PRCP (0.46) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| Hydrochloric Acid SCHEMBL14472340 | 0.98 | PRCP (0.44) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| Hydrochloric Acid SCHEMBL736275 | 0.98 | PRCP (0.44) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| SCHEMBL8266504 | 0.78 | PRCP (0.46) | PRCPCYP19A1TSHRARMEN1 | |
| Hydrochloric Acid SCHEMBL28764877 | 0.78 | HSD11B1 (0.34) | PRCPMEN1KMT2ALMNA | |
| SCHEMBL20915054 | 0.75 | PRCP (0.56) | PRCPCYP19A1TSHRMEN1KMT2A | |
| SCHEMBL445133 | 0.73 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 | |
| SCHEMBL4562 | 0.73 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 | |
| SCHEMBL16106147 | 0.73 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | claimed |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2019-10-24 | — | — | US | claimed |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2017-11-23 | — | — | US | claimed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12398114-B2 | Process for the preparation of ELIGLUSTAT and its intermediate | PIRAMAL PHARMA LIMITED (IN) | 2025-08-26 | — | — | US | disclosed |
| EP-4561565-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4142878-B1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4142878-B1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
| US-6855830-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1409467-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
| WO-2003008399-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | PRCP 1736/4885CYP19A1 3114/4885TSHR 4491/4885 |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | PRCP 1736/4885CYP19A1 3114/4885TSHR 4491/4885 |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | PRCP 1736/4885CYP19A1 3114/4885TSHR 4491/4885 |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | EPOR, FGFR1, ABL1 | PRCP 1424/4885CYP19A1 1003/4885TSHR 2762/4885 |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | PRCP 1736/4885CYP19A1 3114/4885TSHR 4491/4885 |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | PRCP 1736/4885CYP19A1 3114/4885TSHR 4491/4885 |
| US-12398114-B2 | Process for the preparation of ELIGLUSTAT and its intermediate | OGFR, OXGR1, OGFRL1 | PRCP 1064/4885CYP19A1 463/4885TSHR 381/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | PRCP 309/4885CYP19A1 3385/4885TSHR 1077/4885 |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | UGCG, UGGT1, LCLAT1 | PRCP 826/4885CYP19A1 1621/4885TSHR 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.